Clinical Trials

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

NCT07382713 2026-02-03

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

43 enrolled

Ovarian Neoplasms

NCT07353437 2026-01-20

Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)

334 enrolled

Breast Neoplasms

NCT05938374 2025-12-11

SPARE-03

52 enrolled

Phase 1/2 Not yet recruiting

NCT07141771 2025-08-26

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

100 enrolled

Thoracic

SCLC, Extensive Stage

NCT05582499 2025-08-22

FASCINATE-N

716 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3 Recruiting

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Phase 1/2 Recruiting

306 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Phase 3 Completed

252 enrolled

Ovarian Neoplasms

NCT07047066 2025-07-02

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma

30 enrolled

CNS

Glioblastoma

NCT04400188 2025-06-29

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

Phase 1/2 Completed

25 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04102124 2025-06-24

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Phase 2 Terminated

20 enrolled

Prostatic Neoplasms

NCT06827717 2025-05-31

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

29 enrolled

Sarcoma, Ewing

NCT06971211 2025-05-14

PARTOM

40 enrolled

Prostatic Neoplasms

NCT05894018 2025-05-13

RAFAS-001

32 enrolled

NCT04517357 2025-02-24

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

100 enrolled

Ovarian Neoplasms

NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

93 enrolled

Phase 3 Active not recruiting

Metastatic Castration Resistant Prostate Cancer

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

496 enrolled

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06735326 2024-12-16

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

105 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06541314 2024-11-27

Fluzoparib Neoadjuvant Therapy for Ovarian Cancer

48 enrolled

Ovarian Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT06612814 2024-09-25

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

307 enrolled

Breast Cancer Metastatic

NCT06561022 2024-08-19

abemaSNF1/3

260 enrolled

Breast Neoplasms

NCT04228601 2024-08-16

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Phase 1/2 Completed

39 enrolled

Advanced Pancreatic Cancer

NCT06552858 2024-08-14

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

30 enrolled

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT06539091 2024-08-06

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

51 enrolled

Carcinoma, Ovarian Epithelial

NCT06516445 2024-07-24

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

33 enrolled

Colorectal Neoplasms

NCT06446206 2024-06-06

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

22 enrolled

Platinum-sensitive Relapsed Ovarian Cancer

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

117 enrolled

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

NCT04300114 2024-03-28

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Phase 3 Terminated

5 enrolled

Pancreatic Neoplasms

NCT06254066 2024-02-12

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

40 enrolled

Female Breast Cancer Patients

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

766 enrolled

Breast Neoplasms

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

200 enrolled

Phase 3 Not yet recruiting

Breast Cancer Metastatic

NCT06188455 2024-01-03

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

37 enrolled

Ovarian Neoplasms

NCT05223582 2023-12-08

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

34 enrolled

Prostatic Neoplasms

NCT06161272 2023-12-07

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

80 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06074692 2023-10-31

PRIMA

86 enrolled

Sarcoma, Osteosarcoma

NCT06081595 2023-10-13

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

54 enrolled

Ovarian Neoplasms

NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

44 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06055166 2023-09-26

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

120 enrolled

Esophageal Squamous Cell Carcinoma

NCT04718740 2023-08-14

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Phase 1 Completed

33 enrolled

Ovarian Neoplasms

NCT05585281 2023-07-28

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

25 enrolled

Ovarian Neoplasms

NCT05932264 2023-07-06

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Phase 1/2 Unknown

125 enrolled

Triple Negative Breast Neoplasms

NCT04535687 2023-06-13

Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

1 enrolled

Carcinoma, Renal Cell

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Completed

2,336 enrolled

Tumor-Agnostic

Neoplasms

NCT05761470 2023-03-09

IMPARP

66 enrolled

Her-2 Negative Breast Cancer

NCT05732129 2023-02-24

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

29 enrolled

Kenny-Caffey syndrome, Type 1

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

31 enrolled

Other solid neoplasm

Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

32 enrolled